Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

Document first published:
Page updated:
Topic:
Publication type:
,

NHS England will commission emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors in accordance with the criteria outlined in this policy.

Document

Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

  • PDF
  • 308 KB
  • 22 pages

Document

Evidence Review

Evidence Review

  • PDF
  • 446 KB
  • 35 pages

Document

Consultation Report

Consultation Report

  • PDF
  • 103 KB
  • 4 pages

Document

CPAG Summary Report

CPAG Summary Report

  • PDF
  • 103 KB
  • 5 pages

Document

Clinical Panel Report

Clinical Panel Report

  • PDF
  • 129 KB
  • 2 pages